A 56-year-old woman is evaluated in the clinic for follow-up of major depressive disorder.… — USMLE Step 3

A 56-year-old woman is evaluated in the clinic for follow-up of major depressive disorder. Two months ago, she was started on sertraline. She reports that her mood has minimally improved, but she has developed new-onset progressive fatigue, frequent nausea, and mild muscle cramps over the past two weeks. Her medical history is also significant for partial complex seizures, which have been well controlled on levetiracetam for the past five years. Her blood pressure is $128/82 \text{ mmHg}$ , pulse is $76/\text{min}$ , and respirations are $14/\text{min}$ . Physical examination reveals mild lethargy and sluggish deep tendon reflexes, but no focal neurologic deficits. Laboratory studies show:

Laboratory Test	Result
Serum sodium	$121 \text{ mEq/L}$
Serum potassium	$4.0 \text{ mEq/L}$
Blood urea nitrogen	$7 \text{ mg/dL}$
Serum creatinine	$0.7 \text{ mg/dL}$
Urine osmolality	$380 \text{ mOsm/kg H}_2\text{O}$
Urine sodium	$45 \text{ mEq/L}$

A review of her records shows a normal basic metabolic panel three months ago. Sertraline is discontinued, and fluid restriction is initiated for the management of syndrome of inappropriate antidiuretic hormone (SIADH) secretion. The patient continues to experience severe depressive symptoms and requests an alternative treatment.

Which of the following is the most appropriate medication to treat this patient's depression?

A
Bupropion
B
Duloxetine
MirtazapineAnswer
D
Paroxetine
E
Selegiline

Answer

Mirtazapine is the most appropriate next step because it treats depression without significantly risking recurrent SIADH or lowering the seizure threshold.

The correct answer is mirtazapine. The patient has developed syndrome of inappropriate antidiuretic hormone (SIADH) secondary to sertraline use, which is a known adverse effect of selective serotonin reuptake inhibitors (SSRIs). Because SIADH is largely a class effect of both SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs), these agents should be avoided in this patient moving forward. The patient requires an alternative antidepressant that is both safe for her sodium levels and her comorbid seizure disorder. Mirtazapine is an atypical, presynaptic alpha-2 antagonist that is highly effective for major depressive disorder and carries a much lower risk of inducing SIADH. Furthermore, unlike some other atypical antidepressants, it does not significantly lower the seizure threshold, making it the safest choice for this specific patient.

Step-by-Step Solution

Identify the primary adverse drug event and its implications for further treatment.

The patient developed hypotonic hyponatremia with inappropriately concentrated urine (

380 \text{ mOsm/kg}

), indicating SSRI-induced SIADH.

Recognizing the cause of the hyponatremia rules out the future use of serotonergic agents that share this class effect (e.g., other SSRIs or SNRIs).

Identify clinical constraints based on the patient's past medical history.

The patient has a history of partial complex seizures.

Any alternative antidepressant chosen must not significantly lower the seizure threshold.

Evaluate the remaining pharmacologic options against these constraints.

Mirtazapine is selected as the safest and most effective option.

Bupropion lowers the seizure threshold; SSRIs and SNRIs risk recurrent SIADH; MAOIs require a lengthy washout period after stopping an SSRI to prevent serotonin syndrome. Mirtazapine avoids all these pitfalls.

Key Concept

When a patient develops SSRI-induced SIADH, alternative antidepressants outside the SSRI/SNRI classes (such as mirtazapine) should be selected, taking care to avoid agents contraindicated by the patient's other comorbidities (e.g., avoiding bupropion in seizure disorders).

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic